<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656720</url>
  </required_header>
  <id_info>
    <org_study_id>NRL001-01/2011 (SEFI)</org_study_id>
    <nct_id>NCT01656720</nct_id>
  </id_info>
  <brief_title>A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period</brief_title>
  <official_title>A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in
      the treatment of faecal incontinence, compared against placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide data on the efficacy of NRL001 in patients with faecal incontinence over an 8 week treatment period</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide preliminary data on the safety and tolerability of NRL001 (5mg, 7.5mg and 10mg) over an 8 week treatment period compared to placebo</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the population pharmacokinetics and to establish any pharmacokinetic/pharmacodynamic relationship with adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the dose-response relationship in order to identify the appropriate dose(s) of NRL001 for future studies</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment according to the patient's Faecal Incontinence Quality of Life questionnaire at 4 and 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment according to the Vaizey score at 4 and 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">417</enrollment>
  <condition>Faecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2g Suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRL001 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg NRL001 in a 2g suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRL001 7.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7.5mg NRL001 in a 2g suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRL001 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg NRL001 in a 2g suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1R, 2S-methoxamine hydrochloride</intervention_name>
    <arm_group_label>NRL001 5mg</arm_group_label>
    <arm_group_label>NRL001 7.5mg</arm_group_label>
    <arm_group_label>NRL001 10mg</arm_group_label>
    <other_name>NRL001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An ultrasound assessment of the internal anal sphincter within the previous 12 months
             confirming an intact circular internal sphincter with minimal scars (maximum 60
             degrees scarring circumferentially).

          -  Diagnosis of faecal incontinence with a Wexner score of 8 - 20 inclusive at Visit 1 -
             Screening Visit.

          -  Historical clinical evidence (past 6 months prior to Visit 1 - Screening Visit) of
             faecal incontinence episodes (solids, liquid, gas or mucus).

          -  Greater than or equal to two faecal incontinence episodes (solids, liquid, gas or
             mucus) per week during the 4 week historical period prior to Visit 1 - Screening
             Visit.

          -  Able and willing to receive rectal examinations and treatments.

          -  Patients must be aged &gt;18 without significant acute or uncontrolled chronic disease.

          -  Patients must understand the purpose and risks of the study and be able to provide
             written informed consent and willing, able and competent to complete the entire study
             and comply with study instructions as defined in the protocol.

          -  Female patients must be postmenopausal (for at least one year and confirmed by serum
             FSH at screening), or surgically sterile, practicing true sexual abstinence, or using
             Investigator-approved methods of contraception throughout the study until after the
             post study physical examination and have a negative pregnancy test at screening.

          -  Sexually active male patients must use condoms with their partners throughout the
             study and for 90 days after completion of the study in addition to their partner's
             normal mode of contraception.

          -  Male patients must not donate sperm during the study and for 90 days after the
             completion of the study.

          -  Patients taking any continuous medication need to have been on a stable regimen for at
             least 1 month prior to Visit 1 - Screening Visit.

        Exclusion Criteria:

          -  External anal sphincter disruption related to faecal incontinence caused by trauma.

          -  Patients with complicating gastrointestinal (GI) disease including those with
             inflammatory bowel diseases, patients that have received radiotherapy or surgery for
             anal cancer, patients with rectal prolapse, transanal surgery.

          -  Relevant history of or presence of any significant or uncontrolled cardiovascular risk
             including:

               1. Systolic &gt; 160mmHg or Diastolic &gt; 100mmHg. Patients on a stable regimen for &gt; 3
                  months with controlled hypertension prior to Visit 1 - Screening Visit (Systolic
                  &lt; 140mmHg or Diastolic &lt; 90mmHg) can be included.

               2. Abnormal 24 hour Screening Holter: corrected QT interval (QTcf) prolongation with
                  cut-off values of &gt;460 ms for females and &gt;430 ms for males, acute arrhythmia,
                  nocturnal bradycardia with heart rate (HR) &lt; 40bpm, atrial fibrillation, AV block
                  Type II and III, Sick Sinus Syndrome, vasovagal syncope.

               3. Fixed cardiac output states (severe aortic stenosis (AS), hypertrophic
                  obstructive cardiomyopathy (HOCM).

               4. Significant mitral regurgitation (MR).

               5. Cardiac failure (New York Heart Association (NYHA) stage II-IV).

          -  Severe or uncontrolled asthma or chronic obstructive pulmonary disease determined by
             clinical history, physical examination, lung function tests or exercise tolerance

          -  Chronic liver disease (e.g. liver cirrhosis, chronic hepatitis, severe hepatic
             insufficiency).

          -  Vascular claudication after &lt;50 metres walking distance.

          -  Severe renal impairment defined as glomerular filtration rate (GFR) â‰¤ 30 ml/min,
             uncontrolled and reno-vascular end stage renal disease.

          -  Patients with diabetic polyneuropathies.

          -  Any type of chronic diarrhoea or frequent diarrhoea (defined as &gt;5 loose stools per
             day).

          -  Faecal impaction and overflow diarrhoea.

          -  Male patients with clinically diagnosed prostatic hyperplasia.

          -  Clinically significant electrolyte abnormalities, e.g. clinically significant low/high
             potassium and low sodium.

          -  Presence of clinical symptomatic haemorrhoids (grade III and IV), anal fissures or
             anorectal fistulas.

          -  Less than 2 episodes of faecal incontinence (solids, liquid, gas or mucus) per week
             during the 4 week historical period prior to Visit 1 - Screening Visit.

          -  Participation in a clinical drug study during the 90 days preceding the initial dose
             in this study.

          -  Known history of allergy to methoxamine or any other ingredients of the
             Investigational Medicinal Product.

          -  Patients who, in the opinion of the Investigator, are unsuitable for participation in
             the study due to any dependencies, general medical conditions or significant illness
             within two weeks prior to randomisation.

          -  Use of any disallowed concomitant medication or other medication that the Investigator
             believes may affect the study including over-the-counter (OTC) products within 30 days
             prior to the Investigational Medicinal Product administration.

          -  A personal or family history of QTcf prolongation or sudden death.

          -  Patients taking Loperamide (2mg) &gt;8 tablets per day for faecal incontinence either
             alone or in combination with codeine phosphate and/or paracetamol (8/500mg).

          -  Patients using any device for the treatment of faecal incontinence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Siproudhis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Pontchaillou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultni Nemocnice BRNO</name>
      <address>
        <city>Brno</city>
        <zip>620 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologie S R O</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska Nemocnice Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Na Bulovce, Gynekologicko-Porodnicka Klinika</name>
      <address>
        <city>Prague</city>
        <zip>180 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakulni Nemocnice Kralovske</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egk S.R.O Sanatoriu&lt; Sv</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GEP Clinic S.R.O</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice V Motole</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux - Hopital St Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes - Hotel Dieu - Institut Des Maladies De L'Appareil Digestif (IMAD)</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Laurent Siproudhis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen - Hopital De Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum Fur Darm-Und Beckenchirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>14193</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Frauenklink</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMC Pannon Medical Center</name>
      <address>
        <city>Budapest</city>
        <zip>H-1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic for Outpatients, Szakrendelo Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>H-1183</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Albert Szent-Gyorgyi Clinical Center, Faculty of Medicine</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javorszky Odon Hopsital</name>
      <address>
        <city>Vac Argenti</city>
        <zip>H-2600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csolnoky Ferenc Veszprem</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa Di Cura San Pio X</name>
      <address>
        <city>Milano</city>
        <zip>20159</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgia Gastroenterologica</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Unita Operativa Di Chirurgia Generale</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emergenza Urgenza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita Operativa Complessa Gastroenteroloogia A</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita Operativa Complessa Patologia Chirurgica A Indirizzo Gastroenterologico</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General And Proctology Surgeon</name>
      <address>
        <city>Gdow</city>
        <zip>32-420</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne, Wyzszej Szkoly Informatycznej</name>
      <address>
        <city>Glowno</city>
        <zip>95-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Mekmed S.C. Przychondnia Lekarska</name>
      <address>
        <city>Katowice</city>
        <zip>40-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Mikomed</name>
      <address>
        <city>Lodz</city>
        <zip>94-238</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osrodek Badawczo - Leczniczy Zbigniew Zegota</name>
      <address>
        <city>Ostroda</city>
        <zip>14-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lecznica Prosen SMO Private Medical Health Care Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>01-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ars Medica SC</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Valle De Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic De Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USP, Hospital De Marbella</name>
      <address>
        <city>Malaga</city>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Mataro</name>
      <address>
        <city>Mataro</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universtiaria Lozana Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pelvic Floor Centre</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirurgiska Kliniken Universitetssjukhuset</name>
      <address>
        <city>Orebro</city>
        <zip>70362</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enheten For Nedre Abdominell Kirurgi</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Surgical Sciences</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nothern General Hopsital</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <last_update_submitted>June 8, 2015</last_update_submitted>
  <last_update_submitted_qc>June 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Faecal Incontinence</keyword>
  <keyword>Suppository</keyword>
  <keyword>Wexner score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

